Biotech’s long-awaited reset?

After more than three years of slow markets, investors and bankers finally believe the ingredients necessary for biotech growth and outperformance have come together. 

A reset of public and private valuations, coupled with falling interest rates, tech underperformance, increasing demand for deals that are in turn generating aftermarket performance, and rational market reactions to catalysts are all contributing to the sector’s growth potential...